Alosetron

Alosetron
Clinical data
Trade names	Lotronex
AHFS/Drugs.com	Monograph
MedlinePlus	a601230
Routes of; administration	Oral (tablets)
ATC code	A03AE01 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	50–60%
Protein binding	82%
Metabolism	Hepatic (including CYP2C9, CYP3A4 and CYP1A2)
Elimination half-life	1.5–1.7 hours
Excretion	Renal 73%, faecal 24%
Identifiers
	IUPAC name 5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one;
CAS Number	122852-42-0 ;
PubChem CID	2099;
IUPHAR/BPS	2296;
DrugBank	DB00969 ;
ChemSpider	2015 ;
UNII	13Z9HTH115;
KEGG	D07129 ;
ChEBI	CHEBI:253342 ;
ChEMBL	ChEMBL1110 ;
CompTox Dashboard (EPA)	DTXSID6044278 ;
Chemical and physical data
Formula	C17H18N4O
Molar mass	294.358 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1nc[nH]c1CN2CCc4c(C2=O)c3ccccc3n4C;
	InChI InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19) ; Key:JSWZEAMFRNKZNL-UHFFFAOYSA-N ;
	(verify)

Alosetron, sold under the brand name Lotronex among others, is a 5-HT₃ antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in females only.

It was patented in 1987 and approved for medical use in 2002.^[1] It is currently marketed by Prometheus Laboratories Inc. (San Diego). Alosetron was withdrawn from the market in 2000 owing to the occurrence of serious life-threatening gastrointestinal adverse effects, but was reintroduced in 2002 with availability and use restricted.

^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 448. ISBN 9783527607495.

[1] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 448. ISBN 9783527607495.

[1]